Avastin given thumbs up in Europe for lung cancer
July 26th, 2007
A key European panel has recommended that the drug bevacizumab be approved for first-line use in treating the most common form of lung cancer in combination with chemotherapy.
THE SURVIVAL RATE OF LC IS 15.5%.
THAT’S UNACCEPTABLE. WE’RE
HERE TO CHANGE THAT.